Innovent Biologics, Inc. and Sanegene Bio USA Inc. (SanegeneBio) announce that they have entered into a collaboration agreement to co-develop SGB-3908, an siRNA drug candidate targeting angiotensinogen (AGT) for the treatment of hypertension. Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908. SGB-3908 is an IND-enabling stage siRNA drug developed based on SanegeneBio's proprietary LEAD(TM) (Ligand and Enhancer Assisted Delivery) platform.

Innovent strategically invested in the CVM area years ago, and has advanced multiple new-generation pipeline assets into late-stage development. SINTBILO(R) (anti-PCSK9 monoclonal antibody) has been approved for the treatment of hyperlipidemia, mazdutide (GLP-1R/GCGR dual agonist) for the treatment of diabetes and obesity is about to submit its first NDA, IBI311 (IGF-1R monoclonal antibody) for the treatment of hyperuricemia is also in global Phase 3 clinical trials. This collaboration further broadens Innovent's strategic presence in the CVM area.

SGB-3908 has entered into the IND-enabling stage, and SINTBILO®? (anti-PCSK9 Monoclonal antibody) has be approved for the treatment of hyper lipidemia, mazdUTide (GLP-1 R/GCGR dual agonist). Innovent has 10 products in the market, including TYVYT(R) (Sintilimab Injection), BYVASDA(R) (Bevacizumab Injection), SULINNO(R) (Adalimumab Injection), HALPRYZA(R) (Rituximab Injection), Pemazyre(R) (Pemigatinib Oral Inhibitor), olverembatinib, Cyramza(R) (Ramucirumab Injection), Retsevmo(R) (Selpercatinib Capsules), FUCASO(R) (Equecabtagene Autoleucel Injection) and SINTBILO(R).